CR20230302A - MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380) - Google Patents

MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380)

Info

Publication number
CR20230302A
CR20230302A CR20230302A CR20230302A CR20230302A CR 20230302 A CR20230302 A CR 20230302A CR 20230302 A CR20230302 A CR 20230302A CR 20230302 A CR20230302 A CR 20230302A CR 20230302 A CR20230302 A CR 20230302A
Authority
CR
Costa Rica
Prior art keywords
glp
gipr
metabolic disorders
div
antagonists
Prior art date
Application number
CR20230302A
Other languages
English (en)
Inventor
Yuan Cheng
Murielle M Veniant-Ellison
Junming Yie
Jing Xu
Jerry Ryan Holder
Bin Wu
Shu-Chen Lu
Bradley J Herberich
James R Falsey
Kelvin Sham
Chawita Netirojjanakul
Leslie P Miranda
Shanaka Stanislaus
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20230302A publication Critical patent/CR20230302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

Se proveen métodos para tratar enfermedades y trastornos metabólicos usando una composición que comprende una proteína<br /> de unión al antígeno específica para el polipéptido GIPR conjugada a un agonista del receptor GLP-1. En varias modalidades la enfermedad o trastorno metabólico es la diabetes tipo 2, obesidad, dislipidemia, niveles elevados de glucosa, niveles elevados de insulina o nefropatía diabética. En determinadas modalidades la composición comprende un anticuerpo o fragmento funcional de este que comprende una cisteína en uno o más sitio(s) de conjugación donde el agonista del receptor GLP-1 se conjuga al anticuerpo o fragmento funcional de este mediante la cadena lateral del residuo de cisteína.
CR20230302A 2017-01-17 2018-01-16 MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380) CR20230302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447332P 2017-01-17 2017-01-17
PCT/US2018/013918 WO2018136440A1 (en) 2017-01-17 2018-01-16 Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Publications (1)

Publication Number Publication Date
CR20230302A true CR20230302A (es) 2023-08-25

Family

ID=61832572

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20190380A CR20190380A (es) 2017-01-17 2018-01-16 MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR)
CR20230302A CR20230302A (es) 2017-01-17 2018-01-16 MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20190380A CR20190380A (es) 2017-01-17 2018-01-16 MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR)

Country Status (25)

Country Link
US (2) US10905772B2 (es)
EP (1) EP3570885A1 (es)
JP (2) JP7175899B2 (es)
KR (1) KR20190104158A (es)
CN (1) CN110662558B (es)
AR (1) AR110751A1 (es)
AU (1) AU2018210858A1 (es)
BR (1) BR112019014588A2 (es)
CA (1) CA3049023A1 (es)
CL (1) CL2019001963A1 (es)
CO (1) CO2019007685A2 (es)
CR (2) CR20190380A (es)
EA (1) EA201991721A1 (es)
IL (1) IL267660A (es)
JO (1) JOP20190177A1 (es)
MA (1) MA47314A (es)
MX (1) MX2019008462A (es)
NZ (1) NZ754937A (es)
PE (1) PE20191467A1 (es)
PH (1) PH12019501656A1 (es)
SA (1) SA519402246B1 (es)
SG (1) SG11201906525SA (es)
TW (1) TWI708613B (es)
UY (1) UY37568A (es)
WO (1) WO2018136440A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ743474A (en) 2015-12-23 2023-03-31 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
AU2018288852A1 (en) * 2017-06-21 2020-01-02 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
MX2020001327A (es) * 2017-08-04 2020-03-20 Amgen Inc Metodo de conjugacion de cys-acm.
US20220152154A1 (en) 2019-03-08 2022-05-19 Amgen Inc. Growth differentiation factor 15 combination therapy
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2022056494A1 (en) * 2020-09-14 2022-03-17 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
AU2022276998A1 (en) 2021-05-21 2023-12-07 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
CA3221655A1 (en) * 2021-06-09 2022-12-15 Swiftnovo Therapeutics Inc. Therapeutics and methods for treating or ameliorating metabolic disorders
WO2023173132A1 (en) * 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
CN117659189A (zh) * 2022-09-08 2024-03-08 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
ATE304864T1 (de) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
JP2001513512A (ja) 1997-08-08 2001-09-04 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンディン作動剤化合物
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DE69839021T3 (de) 1997-11-14 2013-08-08 Amylin Pharmaceuticals, Llc Neuartige exendin agonisten
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
CZ303120B6 (cs) 1998-12-07 2012-04-11 Societe De Conseils De Recherches Et Dapplications Scientifiques S. A. Sloucenina a farmaceutický prostredek
CA2358107C (en) 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
PT1140145E (pt) 1999-01-14 2005-11-30 Amylin Pharmaceuticals Inc Formulacoes novas de agonistas de exendina e metodos para a sua administracao
EP1143989B1 (en) 1999-01-14 2006-12-13 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DK1171465T3 (da) 1999-03-29 2004-12-13 Uutech Ltd Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CA2396157A1 (en) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
DK1257577T3 (da) 2000-01-27 2004-08-02 Lilly Co Eli Fremgangsmåde til oplösning af glucagon som peptidforbindelse
AU5675701A (en) 2000-05-16 2001-11-26 Sanwa Kagaku Kenkyusho Co Agents for preventing or ameliorating insulin resistance and/or obesity
IL158419A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst Methods and composition for the production of orthoganal trna-aminoacyl trna synthetase pairs
US20050159379A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
JP4566459B2 (ja) 2001-06-07 2010-10-20 株式会社日立製作所 表示装置
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
JPWO2003097031A1 (ja) 2002-05-22 2005-09-15 株式会社三和化学研究所 メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤
US20040029805A1 (en) 2002-06-15 2004-02-12 Wolfe M. Michael Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
JP2006213598A (ja) 2003-03-19 2006-08-17 Sanwa Kagaku Kenkyusho Co Ltd ピラゾロピリミジン化合物及びその用途
CN101974090B (zh) 2003-06-12 2015-06-17 伊莱利利公司 Glp-1类似物融合蛋白质
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7991890B2 (en) 2004-09-30 2011-08-02 Microsoft Corporation Game console communication with a device
EP1809335A2 (en) 2004-10-25 2007-07-25 Cytos Biotechnology AG Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
EP1831252B1 (en) 2004-12-22 2009-07-01 Eli Lilly And Company Glp-1 analog fusion protein formulations
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
MX2007009760A (es) 2005-02-11 2007-11-07 Amylin Pharmaceuticals Inc Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006119905A1 (en) 2005-05-11 2006-11-16 Sanofi-Aventis Use of a gip promoter polymorphism
WO2006125763A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
CA2622069A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
US20090186817A1 (en) 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2008006113A2 (en) 2006-07-07 2008-01-10 The Texas A & M University System Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
WO2008019143A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus
GB0814068D0 (en) 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
CA2733006A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
AU2009280012B2 (en) 2008-08-07 2012-12-06 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN103641906A (zh) 2008-08-07 2014-03-19 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
US20120157379A1 (en) 2009-07-31 2012-06-21 Sheau Yu Hsu Gastric Inhibitory Peptide Variants and Their Uses
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
SG191194A1 (en) 2010-12-22 2013-07-31 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
EP2685257A4 (en) 2011-03-08 2014-10-01 Sanwa Kagaku Kenkyusho Co METHOD OF ANALYSIS
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CA2932325A1 (en) * 2013-12-04 2015-06-11 Innovative Targeting Solutions Inc. G-protein coupled receptor agonists and methods
EP3079722B1 (en) 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Method for thioether conjugation of proteins
MX2016008102A (es) 2013-12-17 2017-05-12 The Metrohealth System Composiciones y métodos para tratar la acumulacion de tejido graso.
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
NZ743474A (en) * 2015-12-23 2023-03-31 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)

Also Published As

Publication number Publication date
US20210154318A1 (en) 2021-05-27
SA519402246B1 (ar) 2023-02-15
CL2019001963A1 (es) 2020-04-03
CR20190380A (es) 2019-11-07
CN110662558B (zh) 2024-04-09
MA47314A (fr) 2019-11-27
US10905772B2 (en) 2021-02-02
EP3570885A1 (en) 2019-11-27
TWI708613B (zh) 2020-11-01
NZ754937A (en) 2023-04-28
US20180311372A1 (en) 2018-11-01
BR112019014588A2 (pt) 2020-02-18
KR20190104158A (ko) 2019-09-06
TW201838648A (zh) 2018-11-01
MX2019008462A (es) 2019-11-21
JP2022184880A (ja) 2022-12-13
SG11201906525SA (en) 2019-08-27
CO2019007685A2 (es) 2019-07-31
JOP20190177A1 (ar) 2019-07-16
JP2020506900A (ja) 2020-03-05
AU2018210858A1 (en) 2019-07-18
WO2018136440A1 (en) 2018-07-26
EA201991721A1 (ru) 2020-04-08
CN110662558A (zh) 2020-01-07
CA3049023A1 (en) 2018-07-26
AR110751A1 (es) 2019-05-02
UY37568A (es) 2018-07-31
PH12019501656A1 (en) 2019-10-28
IL267660A (en) 2019-08-29
JP7175899B2 (ja) 2022-11-21
PE20191467A1 (es) 2019-10-16

Similar Documents

Publication Publication Date Title
CR20230302A (es) MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380)
CO2018007582A2 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
CL2019003332A1 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1.
EA201991345A1 (ru) Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip
AR070844A1 (es) Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
AR105284A1 (es) Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
AR075998A1 (es) Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
EA201991583A1 (ru) Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
AR107190A1 (es) Método para tratar o aliviar trastornos metabólicos usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas del glp-1